Benzoyl 2-methyl indoles as selective PPARγ modulators

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2005-01-17

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMCL.2004.10.068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome proliferator‐activated receptor‐γ: too much of a good thing causes harm

  2004cited by this paper
• The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation

  2003cited by this paper
• Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

  2003cited by this paper
• Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

  2003cited by this paper
• Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors

  2002cited by this paper
• The mechanisms of action of PPARs.

  2002cited by this paper
• The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.

  2000cited by this paper
• PPARγ and the Treatment of Insulin Resistance

  2000cited by this paper
• A Selective Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Modulator Blocks Adipocyte Differentiation but Stimulates Glucose Uptake in 3T3-L1 Adipocytes

  2000cited by this paper
• L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ

  1999cited by this paper
• Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects*

  1999cited by this paper
• Synthesis and biological activity of a novel series of indole-derived PPARγ agonists

  1999cited by this paper
• Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution

  1999cited by this paper
• Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs*

  1997cited by this paper
• Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.

  1996cited by this paper
• [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.

  1994cited by this paper
• Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

  1994cited by this paper
• New applications of the mitsunobu reaction in the synthesis of C-2 N-methyl carbapenems

  1992cited by this paper
• Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds.

  1991cited by this paper
• Homogeneous, palladium(0)-catalyzed exchange deprotection of allylic esters, carbonates and carbamates

  1982cited by this paper

• Shifting the PPARγ conformational ensemble toward a transcriptionally repressive state improves covalent inhibitor efficacy

  2026cites this paper
• A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.

  2025cites this paper
• Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ

  2024cites this paper
• Recent advances and therapeutic applications of PPARγ-targeted ligands based on the inhibition mechanism of Ser273 phosphorylation.

  2024cites this paper
• Exploring fingerprints for antidiabetic therapeutics related to peroxisome proliferator-activated receptor gamma (PPARγ) modulators: A chemometric modeling approach

  2024cites this paper
• Peroxisome Proliferator-Activated Receptor Gene Knockout Promotes Podocyte Injury in Diabetic Mice

  2022cites this paper
• A structural mechanism of nuclear receptor biased agonism

  2022cites this paper
• Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.

  2022cites this paper
• Indazole MRL-871 interacts with PPARγ via a binding mode that induces partial agonism.

  2022cites this paper
• PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action

  2021cites this paper
• PPAR Modulation Through Posttranslational Modification Control

  2021cites this paper
• Design of Novel PPAR Agonist for Neurodegenerative Disease

  2021cites this paper
• Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.

  2020cites this paper
• Assessment of the hypoglycemic effect of Bixin in alloxan-induced diabetic rats: in vivo and in silico studies

  2020influential citation
• Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo

  2020cites this paper
• PPARγ Transcription Deficiency Exacerbates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance in Mice

  2020cites this paper
• Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis

  2020cites this paper
• The PPAR Ω Pocket: Renewed Opportunities for Drug Development

  2020cites this paper
• Molecular Modeling Approach to Study the PPARγ-Ligand Interactions.

  2019cites this paper
• An insight into the medicinal perspective of synthetic analogs of indole: A review.

  2019cites this paper
• Friedel-Crafts Alkylation of Indoles with Trichloroacetimidates.

  2019cites this paper
• Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARγ; a Model for Ligand-Dependent Antagonism.

  2018influential citation
• Optimized Structure-based Methodology for Studying PPARγ Partial Agonists

  2018cites this paper
• A structural mechanism for directing inverse agonism of PPARγ

  2018cites this paper
• Molecular determinants of PPARγ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators.

  2018cites this paper
• The application of molecular modelling in the safety assessment of chemicals: A case study on ligand-dependent PPARγ dysregulation.

  2017cites this paper
• Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.

  2017cites this paper
• Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands

  2017cites this paper
• Development of an ELISA for High-Throughput Screening of Inhibitors of Cdk5-Mediated PPARγ Phosphorylation

  2016cites this paper
• Direct electrophilic trifluoromethylthiolation of N -benzyl indoles using AgSCF 3

  2016cites this paper
• Probing the Complex Binding Modes of the PPARγ Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluoromethyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy.

  2016cites this paper
• Mechanistic elucidation guided by covalent inhibitors for the development of anti-diabetic PPARγ ligands† †Electronic supplementary information (ESI) available: Supplementary figures and tables, experimental methods, procedures for synthesis, and full characterization data of compounds. See DOI: 10.

  2016cites this paper
• 1-/2-/3-Fluoroalkyl-substituted indoles, promising medicinally and biologically beneficial compounds: Synthetic routes, significance and potential applications

  2016cites this paper
• Multitargeted bioactive ligands for PPARs discovered in the last decade

  2016cites this paper
• Fischer Indole Synthesis

  2016cites this paper
• Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.

  2015cites this paper
• PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.

  2015cites this paper
• L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.

  2015cites this paper
• Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists.

  2015cites this paper
• Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity.

  2015cites this paper
• Structural mechanism for signal transduction in RXR nuclear receptor heterodimers

  2015cites this paper
• On the Metabolically Active Form of Metaglidasen: Improved Synthesis and Investigation of Its Peculiar Activity on Peroxisome Proliferator‐Activated Receptors and Skeletal Muscles

  2015cites this paper
• Revisiting PPARγ as a target for the treatment of metabolic disorders

  2014cites this paper
• The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.

  2014cites this paper
• Regulation of Adipocyte Transcription by PPARgamma Ligands

  2014cites this paper
• [Establishment and application of screening methods for non-agonist PPARγ ligand].

  2014cites this paper
• An alternate binding site for PPARγ ligands

  2014cites this paper
• KDT501, a Derivative from Hops, Normalizes Glucose Metabolism and Body Weight in Rodent Models of Diabetes

  2014cites this paper
• Biased Signaling and Conformational Dynamics in Nuclear Hormone Receptors

  2014cites this paper
• Nuclear Receptors and Their Selective Pharmacologic Modulators

  2013cites this paper
• Transient expression, purification and characterisation of human full-length PPARγ2 in HEK293 cells.

  2013cites this paper
• Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer

  2013cites this paper
• Structure-based identification of novel PPAR gamma ligands.

  2013cites this paper
• Regulation of renin expression by the orphan nuclear receptors Nr2f2 and Nr2f6.

  2012cites this paper
• Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.

  2012cites this paper
• Noncanonical mechanisms to regulate nuclear receptor signaling.

  2012cites this paper
• Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.

  2012cites this paper
• Novel Transcriptome Profiling Analyses Demonstrate that Selective Peroxisome Proliferator-Activated Receptor γ (PPARγ) Modulators Display Attenuated and Selective Gene Regulatory Activity in Comparison with PPARγ Full Agonists

  2012cites this paper
• Targeting adipose tissue

  2012cites this paper
• Peroxisome Proliferator-Activated Receptor-γ

  2012cites this paper
• Mode of Peroxisome Proliferator-Activated Receptor γ Activation by Luteolin

  2012cites this paper
• Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.

  2012cites this paper
• GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain

  2012cites this paper
• Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.

  2012cites this paper
• Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

  2011cites this paper
• Regulation of renin gene expression by CTCF, Nr2f2, Nr2f6, Nr4a1 and maintenance of the renin expressing cell

  2011cites this paper
• Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods.

  2011cites this paper
• N-Acetylfarnesylcysteine Is a Novel Class of Peroxisome Proliferator-activated Receptor γ Ligand with Partial and Full Agonist Activity in Vitro and in Vivo*

  2011cites this paper
• Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators.

  2011cites this paper
• PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

  2011cites this paper
• A Combined Ligand‐ and Structure‐Based Virtual Screening Protocol Identifies Submicromolar PPARγ Partial Agonists

  2011cites this paper
• Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity

  2011cites this paper
• Development of a new class of benzoylpyrrole-based PPARα/γ activators.

  2011cites this paper
• Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.

  2010cites this paper
• Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.

  2010cites this paper
• Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

  2010cites this paper
• Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells

  2010cites this paper
• Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis.

  2010cites this paper
• Nuclear Hormone Receptor Medicinal Chemistry

  2010cites this paper
• Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands

  2010cites this paper
• New synthetic derivatives of triterpenoids in the treatment of cancer

  2009cites this paper
• Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.

  2009cites this paper
• PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

  2009cites this paper
• PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

  2009cites this paper
• 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways

  2008cites this paper
• The Differential Interactions of Peroxisome Proliferator-Activated Receptor γ Ligands with Tyr473 Is a Physical Basis for Their Unique Biological Activities

  2008influential citation
• Peroxisome Proliferator-Activated Receptor γ as a Novel Therapeutic Target in Asthma

  2008cites this paper
• Highly functionalized 7-azaindoles as selective PPAR gamma modulators.

  2008cites this paper
• New mechanism-based anticancer drugs that act as orphan nuclear receptor agonists

  2007cites this paper
• Synthesis and structure-activity relationship of novel indene N-oxide derivatives as potent peroxisome proliferator activated receptor γ (PPARγ) agonists

  2007cites this paper
• Partial agonists activate PPARgamma using a helix 12 independent mechanism.

  2007cites this paper
• Fat poetry: a kingdom for PPARγ

  2007cites this paper
• Synthesis and glycogen phosphorylase inhibitor activity of 2,3-dihydrobenzo[1,4]dioxin derivatives.

  2007cites this paper
• A two-stage differential hydrogen deuterium exchange method for the rapid characterization of protein/ligand interactions.

  2007cites this paper
• Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.

  2007cites this paper
• 1,1-Bis(3′-Indolyl)-1-(p-substitutedphenyl)methanes Inhibit Growth, Induce Apoptosis, and Decrease the Androgen Receptor in LNCaP Prostate Cancer Cells through Peroxisome Proliferator-Activated Receptor γ-Independent Pathways

  2007cites this paper
• Selective Modulators of PPAR-γ Activity: Molecular Aspects Related to Obesity and Side-Effects

  2007cites this paper
• Nuclear Hormone Receptor Modulators for the Treatment of Diabetes and Dyslipidemia

  2006cites this paper
• From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.

  2006cites this paper
• Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.

  2006cites this paper